Search results

euronews science - Encouraging progress in Parkinson's therapy

http://www.oxfordbiomedica.co.uk/videos/euronews-science-encouraging-progress-parkinsons-therapy

Capital Network's Lowi says Oxford Biomedica research area is 'novel and promising'

http://www.oxfordbiomedica.co.uk/videos/capital-networks-lowi-says-oxford-biomedica-research-area-novel-and-promising

Oxford Biomedica plans biological and economic balance | IG

http://www.oxfordbiomedica.co.uk/videos/oxford-biomedica-plans-biological-and-economic-balance-ig

Cell and Gene Meeting on the Mesa – October 2016

http://www.oxfordbiomedica.co.uk/videos/cell-and-gene-meeting-mesa-%E2%80%93-october-2016

Oxford Biomedica CEO 'excited' about potential for LentiVector technology

http://www.oxfordbiomedica.co.uk/videos/oxford-biomedica-ceo-excited-about-potential-lentivector-technology

Advanced therapies Investor Day – Novemner 2016

http://www.oxfordbiomedica.co.uk/videos/advanced-therapies-investor-day-%E2%80%93-novemner-2016

Analyst Presentation: Interim results for the six months ended 30 June 2017

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-presentation-interim-results-six-months-ended-30-june-2017

Analyst conference call: Oxford BioMedica and Bioverativ Collaboration

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-conference-call-oxford-biomedica-and-bioverativ-collaboration

Analyst conference call: Preliminary results for the year ended 31 December 2017

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-conference-call-preliminary-results-year-ended-31-december-2017

Analyst conference call: Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-conference-call-oxford-biomedica-and-axovant-sciences-enter-8425-million

Pages